Vatalanib a potent oral tyrosine kinase inhibitor with a selective range of molecular targets, has been extensively investigated and has shown promising results in patients with solid tumors in early trials. Vatalanib selectively inhibits the tyrosine kinase domains of vascular endothelial growth factor (VEGF) receptor tyrosine kinases (important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis), platelet-derived growth factor (PDGF) receptor, and c-KIT. The adverse effects of vatalanib appear similar to those of other VEGF inhibitors. In the CONFIRM trials, the most common side effects were high blood pressure, gastrointestinal upset (diarrhea, nausea, and vomiting), fatigue, and dizziness.

Cyclazocine is a mixed opioid agonist/antagonist, an agonist of kappa opioid receptor, and a partial agonist of mu opioid receptor. The drug has analgesic activity and dose 0.25-0.5 mg/70 kg is equivalent to 10 mg/75 kg of morphine. Cyclazocine is a long-acting mu-opioid antagonist in human and was studied for the treatment of addiction to opioids and cocaine. Induction of the drug leads to dysphoria, hallucination, irritability, and sleeplessness.

Diacetamate (Acetaminophen Acetate, Acetaminophen Impurity, diacetyl-p-aminophenol) is a acetaminophen synthetic impurity. Acetaminophen-aspirin mixtures have lower stability due to acetylation of the former by the latter, producing diacetyl-p-aminophenol.

Diampromide is a synthetic narcotic analgesic. It was designed as a methadone analog and hence with a chiral center similar to that of the parent. Diampromide approximates to the potency of pethidine and morphine in mice and rats, respectively. It has been evaluated in postoperative pain. Diampromide is not found in any pharmaceutical preparations sold in the United States. It is under international control according to the UN Single Convention 1961 and its amendments, Schedule I.

FENIMIDE, a succinimide derivative, is an antipsychotic drug. It is not found in any pharmaceutical preparations sold in the US. It was found that FENIMIDE produced a sedative effect prior to deeper central nervous system depression.

Betamethadol or β-methadol is an opioid analgesic under international control according to the UN Single Convention 1961. Betamethadol is an isomer of the racemic mixture of dimepheptanol.

Talviraline (HBY 097) was developed as a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (NNRTI) for the treatment of HIV Infections. Talviraline participated in a phase II clinical trial. It was found that the drug caused pronounced acute suppression of HIV-1 replication both in combination with zidovudine and alone. However, further development of the drug has been discontinued.

Torcetrapib is a CETP inhibitor which was developed by Pfizer for the treatment of diseases associated with elevated level of cholesterol. The drug was tested in phase III (in combination with atorvastatin) of clinical trials in coronary heart disease patients as well as in patients with hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, however its development was terminated due to the high risk of death and heart problems.

Norpipanone (Orfenso; Hexalgon) is an opioid analgesic. It is a controlled substance (opiate).